These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 7755361

  • 21. Huntington's disease: neurological assessment of potential gene carriers presenting for predictive DNA testing.
    McCusker E, Richards F, Sillence D, Wilson M, Trent RJ.
    J Clin Neurosci; 2000 Jan; 7(1):38-41. PubMed ID: 10847649
    [Abstract] [Full Text] [Related]

  • 22. Modeling longitudinal change in motor and cognitive processing speed in presymptomatic Huntington's disease.
    Maroof DA, Gross AL, Brandt J.
    J Clin Exp Neuropsychol; 2011 Oct; 33(8):901-9. PubMed ID: 21644140
    [Abstract] [Full Text] [Related]

  • 23. Predictive testing for Huntington disease: interpretation and significance of intermediate alleles.
    Semaka A, Creighton S, Warby S, Hayden MR.
    Clin Genet; 2006 Oct; 70(4):283-94. PubMed ID: 16965319
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Prefrontal cortex volume reduction on MRI in preclinical Huntington's disease relates to visuomotor performance and CAG number.
    Gómez-Ansón B, Alegret M, Muñoz E, Monté GC, Alayrach E, Sánchez A, Boada M, Tolosa E.
    Parkinsonism Relat Disord; 2009 Mar; 15(3):213-9. PubMed ID: 18632301
    [Abstract] [Full Text] [Related]

  • 26. Complex movement behaviour and progression of Huntington's disease.
    Andrich J, Saft C, Ostholt N, Müller T.
    Neurosci Lett; 2007 Apr 18; 416(3):272-4. PubMed ID: 17321683
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The relationship between CAG repeat length and clinical progression in Huntington's disease.
    Ravina B, Romer M, Constantinescu R, Biglan K, Brocht A, Kieburtz K, Shoulson I, McDermott MP.
    Mov Disord; 2008 Jul 15; 23(9):1223-7. PubMed ID: 18512767
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Cognitive decline in Huntington's disease expansion gene carriers.
    Baake V, Reijntjes RHAM, Dumas EM, Thompson JC, REGISTRY Investigators of the European Huntington's Disease Network, Roos RAC.
    Cortex; 2017 Oct 15; 95():51-62. PubMed ID: 28843844
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Motor dysfunction influence on executive functioning in manifest and premanifest Huntington's disease.
    Hart EP, Dumas EM, Schoonderbeek A, Wolthuis SC, van Zwet EW, Roos RA.
    Mov Disord; 2014 Mar 15; 29(3):320-6. PubMed ID: 24500841
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Biological markers of cognition in prodromal Huntington's disease: a review.
    Papp KV, Kaplan RF, Snyder PJ.
    Brain Cogn; 2011 Nov 15; 77(2):280-91. PubMed ID: 21889251
    [Abstract] [Full Text] [Related]

  • 38. The functional implications of motor, cognitive, psychiatric, and social problem-solving states in Huntington's disease.
    Van Liew C, Gluhm S, Goldstein J, Cronan TA, Corey-Bloom J.
    Psychiatry; 2013 Nov 15; 76(4):323-35. PubMed ID: 24299091
    [Abstract] [Full Text] [Related]

  • 39. Factors contributing to institutionalization in patients with Huntington's disease.
    Rosenblatt A, Kumar BV, Margolis RL, Welsh CS, Ross CA.
    Mov Disord; 2011 Aug 01; 26(9):1711-6. PubMed ID: 21538527
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.